Third-line Sorafenib after sequential therapy with Sunitinib and mTOR ... - UroToday PDF Print
UroTodaySunitinib and everolimus have been approved for first- and second-line treatment, respectively, in metastatic renal cell carcinoma (mRCC).

... read more

 
Share |
Copyright © 2026 Global Dialysis. All Rights Reserved.